Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Acetylcholine receptor (AChR) antibodies are specific proteins that can be found in the bloodstream of individuals diagnosed with myasthenia gravis (MG), a rare neuromuscular disorder characterized by muscle weakness and fatigue. Myasthenia gravis can manifest in two primary forms: ocular myasthenia gravis, which primarily affects the eye muscles, and generalized myasthenia gravis, which impacts a broader range of voluntary muscles throughout the body. Symptoms associated with ocular myasthenia gravis may include drooping eyelids, double vision, and weakness in the eye muscles. In contrast, generalized myasthenia gravis can lead to more severe symptoms, such as weakness in neck muscles, difficulties with chewing, swallowing, or speaking, slurred speech, and challenges with walking or breathing. It is noteworthy that approximately 15% of individuals with myasthenia gravis experience only ocular symptoms. The presence of AChR antibodies disrupts the normal communication between nerves and muscles by interfering with the action of acetylcholine, which is the neurotransmitter responsible for transmitting signals from nerves to muscles. Specifically, modulating antibodies can cause the receptors to be internalized within the cell membrane and subsequently degraded, resulting in reduced expression of these receptors and potentially correlating with increased severity of the disease. To diagnose the presence of AChR antibodies, a sample of venous blood is collected, and semi-quantitative flow cytometry is employed for testing. A positive result can confirm the diagnosis in symptomatic individuals; however, it is important to note that elevated AChR antibody levels may also be observed in patients with thymoma, a type of tumor associated with the thymus gland. It is estimated that only 10% to 15% of individuals with myasthenia gravis will test negative for AChR antibodies, necessitating further testing for other antibodies, such as muscle-specific kinase (MuSK) antibodies. The modulating antibody test is typically conducted when AChR binding antibody levels fall within an indeterminate range of 25% to 41%, with levels of 46% or higher being classified as positive. However, the likelihood of detecting modulating antibodies in patients who are negative for binding and blocking antibodies is less than 0.4%.
© Copyright 2026 Coding Ahead. All rights reserved.
The acetylcholine receptor (AChR) modulating antibody test is indicated for individuals who exhibit symptoms consistent with myasthenia gravis (MG). The following conditions and symptoms warrant the performance of this test:
The procedure for testing AChR modulating antibodies involves several key steps, which are outlined below:
Post-procedure care following the AChR modulating antibody test is generally minimal, as the blood draw is a routine procedure. Patients may experience slight discomfort or bruising at the site of the blood draw, which typically resolves quickly. It is important for healthcare providers to communicate the results of the test to the patient, discussing the implications of positive or negative findings. If the test is positive, further management and treatment options for myasthenia gravis may be explored. In cases where the test results are inconclusive or negative, additional testing for other antibodies, such as muscle-specific kinase (MuSK) antibodies, may be recommended to ensure an accurate diagnosis and appropriate treatment plan.
| Short Descr | ACETYLCHOLN RCPTR MODLG ANTB | Medium Descr | ACETYLCHOLINE RECEPTOR MODULATING ANTIBODY | Long Descr | Acetylcholine receptor (AChR); modulating antibody | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GZ | Item or service expected to be denied as not reasonable and necessary |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2024-01-01 | Added | Code Added. |
Get instant expert-level medical coding assistance.